---
title: "Paxlovid (nirmatrelvir; ritonavir), all indications: Specific populations questions"
description: "Specific populations questions on Paxlovid (nirmatrelvir; ritonavir) that apply to every indication, each answered with verbatim quotes from the manufacturer's US website for healthcare professionals or documents it links. Topics: Pregnancy and breastfeeding and Pediatric use. Questions: Can Paxlovid be used during pregnancy? Can Paxlovid be used while breastfeeding? Is Paxlovid approved for children? Can Paxlovid be used in patients with liver disease (hepatic impairment)? 1 further question follow. 5 questions quoted from 2 sources."
canonical: "https://www.evicenter.com/medical-information/paxlovid/specific-populations"
published: "2026-11-14T01:54:55-05:00"
modified: "2026-11-14T15:19:23-05:00"
---

# Paxlovid (nirmatrelvir; ritonavir), all indications: Specific populations questions

Manufacturer: Pfizer Inc  
Prescribing information: [Paxlovid](https://labeling.pfizer.com/ShowLabeling.aspx?id=19599)  
Indication pages: [COVID-19](https://www.evicenter.com/medical-information/paxlovid--covid-19)

## Pregnancy and breastfeeding

<a id="paxlovid-pregnancy"></a>

### Can Paxlovid be used during pregnancy?

> “Available data on the use of nirmatrelvir during pregnancy are insufficient to evaluate for a drug-associated risk of major birth defects, miscarriage, or adverse maternal or fetal outcomes. Published observational studies on ritonavir use in pregnant women have not identified an increase in the risk of major birth defects. Published studies with ritonavir are insufficient to identify a drug associated risk of miscarriage (see Data). There are maternal and fetal risks associated with untreated COVID-19 in pregnancy (see Clinical Considerations).”

Source: [PAXLOVID: Prescribing information, captured 2026-11-13](https://labeling.pfizer.com/ShowLabeling.aspx?id=19599#:~:text=Available%20data%20on%20the%20use,in%20pregnancy%20%28see%20Clinical%20Considerations%29.)

> “COVID-19 in pregnancy is associated with adverse maternal and fetal outcomes, including preeclampsia, eclampsia, preterm birth, premature rupture of membranes, venous thromboembolic disease, and fetal death.”

Source: [PAXLOVID: Prescribing information, captured 2026-11-13](https://labeling.pfizer.com/ShowLabeling.aspx?id=19599#:~:text=COVID%2D19%20in%20pregnancy%20is%20associated,thromboembolic%20disease%2C%20and%20fetal%20death.)

<a id="paxlovid-breastfeeding"></a>

### Can Paxlovid be used while breastfeeding?

> “Nirmatrelvir and ritonavir are present in human breast milk in small amounts (less than 2%). In a clinical lactation study in 8 lactating women, nirmatrelvir and ritonavir were estimated to be present in human milk at a mean weight-normalized infant daily dose of 0.16 mg/kg/day (1.8% of maternal weight-adjusted daily dose) and 0.006 mg/kg/day (0.2% of maternal weight-adjusted daily dose), respectively (see Data).
>
> There are no available data on the effects of nirmatrelvir or ritonavir on the breastfed infant or on milk production. The developmental and health benefits of breastfeeding should be considered along with the mother's clinical need for PAXLOVID and any potential adverse effects on the breastfed infant from PAXLOVID or from the underlying maternal condition. Breastfeeding individuals with COVID-19 should follow practices according to clinical guidelines to avoid exposing the infant to COVID-19.”

Source: [PAXLOVID: Prescribing information, captured 2026-11-13](https://labeling.pfizer.com/ShowLabeling.aspx?id=19599#:~:text=Nirmatrelvir%20and%20ritonavir%20are%20present,exposing%20the%20infant%20to%20COVID%2D19.)

## Pediatric use

<a id="paxlovid-children"></a>

### Is Paxlovid approved for children?

> “The optimal dose of PAXLOVID has not been established in pediatric patients.”

Source: [PAXLOVID: Prescribing information, captured 2026-11-13](https://labeling.pfizer.com/ShowLabeling.aspx?id=19599#:~:text=The%20optimal%20dose%20of%20PAXLOVID%20has%20not%20been%20established%20in%20pediatric%20patients.)

> “The pharmacokinetics of nirmatrelvir/ritonavir in patients less than 18 years of age have not been established.”

Source: [PAXLOVID: Prescribing information, captured 2026-11-13](https://labeling.pfizer.com/ShowLabeling.aspx?id=19599#:~:text=The%20pharmacokinetics%20of%20nirmatrelvir%2Fritonavir%20in,age%20have%20not%20been%20established.)

> “PAXLOVID is not approved for use in pediatric patients.<sup>3</sup>”

Source: [PAXLOVID: High Risk Factors, captured 2026-11-13](https://paxlovid.pfizerpro.com/about-paxlovid/high-risk-factor#:~:text=PAXLOVID%20is%20not%20approved%20for%20use%20in%20pediatric)

Note: These passages describe the approved label. Use under emergency use authorization is not covered here.

## Specific populations

<a id="paxlovid-liver-disease"></a>

### Can Paxlovid be used in patients with liver disease (hepatic impairment)?

> “No dosage adjustment is needed in patients with mild (Child-Pugh Class A) or moderate (Child-Pugh Class B) hepatic impairment.
>
> No pharmacokinetic or safety data are available regarding the use of nirmatrelvir or ritonavir in subjects with severe (Child-Pugh Class C) hepatic impairment; therefore, PAXLOVID is not recommended for use in patients with severe hepatic impairment [see Use in Specific Populations (8.7)].”

Source: [PAXLOVID: Prescribing information, captured 2026-11-13](https://labeling.pfizer.com/ShowLabeling.aspx?id=19599#:~:text=No%20dosage%20adjustment%20is%20needed,Use%20in%20Specific%20Populations%20%288.7%29%5D.)

> “The pharmacokinetics of nirmatrelvir were similar in patients with moderate (Child-Pugh Class B) hepatic impairment compared to healthy subjects following administration of a single oral dose of nirmatrelvir 100 mg (0.33 times the approved recommended dose) co-administered with ritonavir 100 mg. The impact of severe hepatic impairment (Child-Pugh Class C) on the pharmacokinetics of nirmatrelvir or ritonavir has not been studied.”

Source: [PAXLOVID: Prescribing information, captured 2026-11-13](https://labeling.pfizer.com/ShowLabeling.aspx?id=19599#:~:text=The%20pharmacokinetics%20of%20nirmatrelvir%20were%20similar,ritonavir%20has%20not%20been%20studied.)

<a id="paxlovid-overdose"></a>

### What should be done after a Paxlovid overdose?

> “Treatment of overdose with PAXLOVID should consist of general supportive measures including monitoring of vital signs and observation of the clinical status of the patient. There is no specific antidote for overdose with PAXLOVID.”

Source: [PAXLOVID: Prescribing information, captured 2026-11-13](https://labeling.pfizer.com/ShowLabeling.aspx?id=19599#:~:text=Treatment%20of%20overdose%20with%20PAXLOVID,antidote%20for%20overdose%20with%20PAXLOVID.)

> “If you take too much PAXLOVID, call your healthcare provider or go to the nearest hospital emergency room right away.”

Source: [PAXLOVID: Prescribing information, captured 2026-11-13](https://labeling.pfizer.com/ShowLabeling.aspx?id=19599#:~:text=If%20you%20take%20too%20much,hospital%20emergency%20room%20right%20away.)

## Related pages
- [Medical information: Paxlovid (nirmatrelvir; ritonavir): All indications](https://www.evicenter.com/medical-information/paxlovid)
- [Indication](https://www.evicenter.com/medical-information/paxlovid/indication)
- [Pharmacology](https://www.evicenter.com/medical-information/paxlovid/pharmacology)
- [Clinical trials](https://www.evicenter.com/medical-information/paxlovid/clinical-trials)
- [Safety](https://www.evicenter.com/medical-information/paxlovid/safety)
- [Drug interactions](https://www.evicenter.com/medical-information/paxlovid/drug-interactions)
- [Dosing and administration](https://www.evicenter.com/medical-information/paxlovid/dosing-and-administration)
- [Storage and supply](https://www.evicenter.com/medical-information/paxlovid/storage-and-supply)
- [Access and coverage](https://www.evicenter.com/medical-information/paxlovid/access-and-coverage)
